Ildiko Lingvay

42.4k total citations · 21 hit papers
220 papers, 15.6k citations indexed

About

Ildiko Lingvay is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Ildiko Lingvay has authored 220 papers receiving a total of 15.6k indexed citations (citations by other indexed papers that have themselves been cited), including 190 papers in Endocrinology, Diabetes and Metabolism, 109 papers in Molecular Biology and 53 papers in Surgery. Recurrent topics in Ildiko Lingvay's work include Diabetes Treatment and Management (165 papers), Metabolism, Diabetes, and Cancer (105 papers) and Diabetes Management and Research (70 papers). Ildiko Lingvay is often cited by papers focused on Diabetes Treatment and Management (165 papers), Metabolism, Diabetes, and Cancer (105 papers) and Diabetes Management and Research (70 papers). Ildiko Lingvay collaborates with scholars based in United States, Denmark and United Kingdom. Ildiko Lingvay's co-authors include Melanie J. Davies, Thomas A. Wadden, Julio Rosenstock, Sean Wharton, Robert F. Kushner, John Wilding, Luc F. Van Gaal, Koutaro Yokote, Barbara McGowan and Rachel L. Batterham and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Ildiko Lingvay

208 papers receiving 15.3k citations

Hit Papers

Once-Weekly Semaglutide in Adults with Overweigh... 2017 2026 2020 2023 2021 2023 2019 2021 2021 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity
    2021 2.5k citations Melanie J. Davies, Ildiko Lingvay et al. profile →
  2. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
    2023 1.3k citations A. Michael Lincoff, Kirstine Brown‐Frandsen et al. profile →
  3. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    2019 1.2k citations Ole Kleist Jeppesen, Ildiko Lingvay et al. profile →
  4. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
    2021 806 citations Melanie J. Davies, Ole Kleist Jeppesen et al. profile →
  5. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
    2021 646 citations Melanie J. Davies, Ildiko Lingvay et al. profile →
  6. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
    2018 559 citations Richard E. Pratley, Ildiko Lingvay et al. profile →
  7. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
    2022 515 citations Melanie J. Davies, Ildiko Lingvay et al. Diabetes Obesity and Metabolism profile →
  8. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
    2017 438 citations Ildiko Lingvay et al. profile →
  9. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
    2019 411 citations Richard E. Pratley, Søren T. Hoff et al. profile →
  10. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
    2021 349 citations Ildiko Lingvay et al. profile →
  11. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
    2023 193 citations Ildiko Lingvay, Melanie J. Davies et al. profile →
  12. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
    2022 158 citations John A. Spertus, Mary C. Birmingham et al. Nature Medicine profile →
  13. Semaglutide for the treatment of overweight and obesity: A review
    2022 130 citations Melanie J. Davies, Ildiko Lingvay et al. Diabetes Obesity and Metabolism profile →
  14. Obesity in adults
    2024 124 citations Ildiko Lingvay et al. profile →
  15. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
    2024 123 citations Mikhail Kosiborod, John Deanfield et al. profile →
  16. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
    2024 123 citations Donna H. Ryan, Ildiko Lingvay et al. Nature Medicine profile →
  17. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
    2024 102 citations Helen M. Colhoun, Ildiko Lingvay et al. Nature Medicine profile →
  18. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
    2024 100 citations John Deanfield, Subodh Verma et al. profile →
  19. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin
    2023 91 citations Amoolya Gowda, Ildiko Lingvay et al. profile →
  20. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes
    2023 84 citations Ildiko Lingvay, André Gustavo Daher Vianna et al. profile →
  21. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
    2025 19 citations Melanie J. Davies, Harpreet S. Bajaj et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ildiko Lingvay United States 52 11.2k 5.2k 4.6k 3.8k 3.3k 220 15.6k
Tina Vilsbøll Denmark 73 14.9k 1.3× 7.0k 1.3× 2.6k 0.6× 8.1k 2.1× 3.4k 1.0× 455 20.3k
Juan P. Frías United States 48 8.3k 0.7× 3.9k 0.7× 3.1k 0.7× 2.8k 0.7× 2.4k 0.7× 172 11.4k
Filip K. Knop Denmark 74 12.4k 1.1× 6.0k 1.1× 2.4k 0.5× 7.7k 2.0× 3.7k 1.1× 552 18.8k
Ofri Mosenzon Israel 40 13.3k 1.2× 5.4k 1.0× 2.1k 0.5× 4.8k 1.3× 1.2k 0.4× 142 15.9k
Alan J. Garber United States 51 9.1k 0.8× 3.9k 0.7× 1.8k 0.4× 3.8k 1.0× 2.1k 0.6× 142 13.3k
Robert E. Ratner United States 60 10.7k 1.0× 3.7k 0.7× 1.5k 0.3× 5.1k 1.3× 1.8k 0.6× 159 16.6k
Uli C. Broedl Germany 55 18.6k 1.7× 8.3k 1.6× 2.6k 0.6× 9.2k 2.4× 2.0k 0.6× 118 23.1k
Odd Erik Johansen United States 35 14.8k 1.3× 5.8k 1.1× 1.8k 0.4× 6.3k 1.6× 1.4k 0.4× 123 17.8k
Giorgio Sesti Italy 67 6.9k 0.6× 5.6k 1.1× 942 0.2× 3.4k 0.9× 2.8k 0.9× 416 15.1k
Michel Marre France 66 8.7k 0.8× 3.9k 0.8× 1.4k 0.3× 3.3k 0.9× 2.3k 0.7× 423 17.2k

Countries citing papers authored by Ildiko Lingvay

Since Specialization
Citations

This map shows the geographic impact of Ildiko Lingvay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ildiko Lingvay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ildiko Lingvay more than expected).

Fields of papers citing papers by Ildiko Lingvay

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ildiko Lingvay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ildiko Lingvay. The network helps show where Ildiko Lingvay may publish in the future.

Co-authorship network of co-authors of Ildiko Lingvay

This figure shows the co-authorship network connecting the top 25 collaborators of Ildiko Lingvay. A scholar is included among the top collaborators of Ildiko Lingvay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ildiko Lingvay. Ildiko Lingvay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Philis‐Tsimikas, Athena, Jens Aberle, Harpreet S. Bajaj, et al.. (2025). Clinical Use of Once-Weekly Insulin Icodec: Translating Clinical Trial Data into Practical Guidance for Diabetes Management. Drugs. 85(10). 1253–1268.
2.
Messiah, Sarah, Folefac Atem, M. Sunil Mathew, et al.. (2025). Metabolic and Bariatric Surgery Utilization in the Era of Glucagon-Like Peptide-1 Receptor Agonists among Adolescents versus Adults. The Journal of Pediatrics. 282. 114564–114564. 2 indexed citations
3.
Gudzune, Kimberly A., et al.. (2024). #1696673 Weight reduction over time in tirzepatide-treated participants by early weight loss response – post hoc analysis in SURMOUNT-1. Endocrine Practice. 30(5). S66–S66. 2 indexed citations
4.
Verma, Subodh, Helen M. Colhoun, Dror Dicker, et al.. (2024). Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT). Journal of the American College of Cardiology. 84(17). 1678–1682. 11 indexed citations
5.
Scirica, Benjamin M., A. Michael Lincoff, Ildiko Lingvay, et al.. (2024). The Effect of Semaglutide on Mortality and COVID-19–Related Deaths. Journal of the American College of Cardiology. 84(17). 1632–1642. 22 indexed citations
6.
Brown‐Frandsen, Kirstine, Helen M. Colhoun, John Deanfield, et al.. (2024). Semaglutide and cardiovascular outcomes in patients with overweight or obesity who do not have diabetes. Obesity Research & Clinical Practice. 18(5). S36–S36. 1 indexed citations
7.
Pournaras, Dimitri J., et al.. (2024). Better together: antiobesity medications and bariatric surgery for the management of obesity. British journal of surgery. 111(12). 1 indexed citations
8.
Štambuk, Tamara, Domagoj Kifer, Niall Dempster, et al.. (2024). Alterations in plasma protein N-glycosylation after caloric restriction and bariatric surgery. Surgery for Obesity and Related Diseases. 20(6). 587–596. 1 indexed citations
9.
Caramori, Maria Luiza, David Z.I. Cherney, Jill P. Crandall, et al.. (2024). Albuminuria and Rapid Kidney Function Decline as Selection Criteria for Kidney Clinical Trials in Type 1 Diabetes Mellitus. Clinical Journal of the American Society of Nephrology. 20(1). 62–71. 2 indexed citations
10.
Álvarez, Carlos A., et al.. (2024). Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease. Nature Communications. 15(1). 10623–10623. 5 indexed citations
11.
Lingvay, Ildiko, Ofri Mosenzon, Katelyn Brown, et al.. (2023). Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovascular Diabetology. 22(1). 66–66. 37 indexed citations
12.
Harrington, Josephine, G. Michael Felker, Ildiko Lingvay, et al.. (2023). Managing Obesity in Heart Failure. JACC Heart Failure. 12(1). 28–34. 4 indexed citations
13.
Bajaj, Harpreet S., Jens Aberle, Melanie J. Davies, et al.. (2023). Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5). Annals of Internal Medicine. 176(11). 1476–1485. 57 indexed citations
14.
Spertus, John A., Mary C. Birmingham, Michael E. Nassif, et al.. (2022). The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nature Medicine. 28(4). 809–813. 158 indexed citations breakdown →
15.
Lingvay, Ildiko, Andrei‐Mircea Catarig, Jack Lawson, et al.. (2022). An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes. Diabetes Therapy. 14(1). 123–137. 1 indexed citations
16.
Spertus, John A., Mary C. Birmingham, Javed Butler, et al.. (2021). Novel Trial Design: CHIEF-HF. Circulation Heart Failure. 14(3). e007767–e007767. 22 indexed citations
17.
Pratley, Richard E., Andrei‐Mircea Catarig, Ildiko Lingvay, et al.. (2021). An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg. Diabetes Obesity and Metabolism. 23(11). 2513–2520. 17 indexed citations
18.
Lingvay, Ildiko, Nadine Beetz, Regina Sennewald, et al.. (2020). Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. Postgraduate Medicine. 132(4). 337–345. 17 indexed citations
19.
Lingvay, Ildiko, et al.. (2020). 1211-P: Real-World Use of SGLT2 Inhibitors in a Large U.S. Safety-Net Health System. Diabetes. 69(Supplement_1). 2 indexed citations
20.
Pop, Laurentiu M., Shirley Yan, & Ildiko Lingvay. (2012). A Rare Case of De novo C634G Germline Mutation of the RET Proto-Oncogene in a Patient With MEN 2A Syndrome With Aggressive Pheochromocytoma. Journal of Endocrinology and Metabolism. 2. 198–204.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tina Vilsbøll Breakdown of academic impact, for papers by Juan P. Frías Breakdown of academic impact, for papers by Filip K. Knop Breakdown of academic impact, for papers by Ofri Mosenzon Breakdown of academic impact, for papers by Alan J. Garber Breakdown of academic impact, for papers by Robert E. Ratner Breakdown of academic impact, for papers by Uli C. Broedl Breakdown of academic impact, for papers by Odd Erik Johansen Breakdown of academic impact, for papers by Giorgio Sesti Breakdown of academic impact, for papers by Michel Marre
Rankless by CCL
2026